What are you searching for?

Sign in
Features

2008 Top 20 Pharmaceutical Companies Report

The weak U.S. dollar played a strong role in this year’s Top 20 Pharma Report. Several overseas players look a lot better than they should, thanks to my insistence on converting all results to dollars. In local currencies, many foreign and domestic players were barely able to eke out growth in 2007.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

2008 Top 20 Pharmaceutical Companies Report

The weak U.S. dollar played a strong role in this year’s Top 20 Pharma Report. Several overseas players look a lot better than they should, thanks to my insistence on converting all results to dollars. In local currencies, many foreign and domestic players were barely able to eke out growth in 2007. Several companies still managed to post solid gains during the year, but even they were haunted by the specter of patent expirations to come.

It was a tough year at many of these companies, with layoffs reaching the tens of thousands. New leadership teams, with chief executives not much older than your humble editor, have inherited truly untenable situations.

—Gil Y. Roth, Editor

 

Top 20 Pharmaceutical Companies
01 Pfizer $44,424
02 GlaxoSmithKline $38,501
03 Sanofi-Aventis $38,452
04 AstraZeneca $28,713
05 Merck $26,532
06 Novartis $25,477
07 Johnson & Johnson $24,866
08 Roche $21,998
09 Eli Lilly & Co. $17,638
10 Wyeth $17,179
11 Bristol-Myers Squibb $15,622
12 Abbott Laboratories $14,632
13 Schering-Plough $12,773
14 Bayer Schering $12,294
15 Boehringer Ingelheim $11,103
16 Takeda $10,626
17 Astellas* $8,530
18 Daiichi-Sankyo* $7,382
19 Eisai* $6,250
20 UCB Group* $4,370

Based on 2007 pharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
For the pipeline and patent expiry info, download the PDFs of the profiles, available within each company’s page.

* PDF profiles only available for companies 17-20

 

Contributors


Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe

All profiles written by Gil Roth, except Abbott Laboratories, by Kristin Brooks.

The Lowe Down capsules written by Derek Lowe

All pipeline information compiled by Kristin Brooks

Sales information compiled by Gil Roth

Looking for the Top 10 Biopharma companies report? Look no further!

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics